Protein interactions demonstrate that Alzheimer’s and Parkinson’s may share a common fiber

From: Kathrynne Holden, MS, RD (fivestar@nutritionucanlivewith.com)
Date: Fri Apr 25 2003 - 04:18:31 PDT

  • Next message: Bonnie Athas: "Legislative update for GN Membership"

    Contact: Greg Lester
    lesterg@uphs.upenn.edu
    215-349-5658
    University of Pennsylvania Medical Center

    Protein interactions demonstrate that Alzheimer’s and Parkinson’s
    disease may share a common fiber

    Tau and alpha-synuclein proteins encourage each other to produce brain
    lesions

    (Philadelphia, PA) – The amyloid lesions that cause Alzheimer’s and
    Parkinson’s disease are made of clumps of tangled proteins, but these
    clumps are composed of different protein subunits. Researchers at the
    University of Pennsylvania School of Medicine have discovered, however,
    that the tau proteins found in Alzheimer’s disease and the alpha
    (?)-synuclein proteins found in Parkinson’s disease can facilitate each
    other to form amyloid lesions in the laboratory.

    Their findings, presented in this week’s issue of Science, provide
    insights into the mechanisms underlying both diseases and suggest that
    therapeutics developed for one disease might be efficacious for both.

    “We are trying to understand the basic pathological overlap between the
    different amyloid lesions that cause Alzheimer’s and Parkinson’s, ” said
    Virginia M. -Y. Lee, PhD, professor in Penn’s Department of Pathology
    and Laboratory Medicine and Director of Penn’s Center for
    Neurodegenerative Disease Research (CNDR). “This fundamental
    relationship may explain why patients with one disease are more likely
    to exhibit signs of the other disease.”

    The researchers showed that the ?-synuclein proteins that form Lewy
    bodies in Parkinson’s disease can induce tau proteins to form the sort
    of fiber aggregates found in Alzheimer’s disease. Moreover, interactions
    between the tau and the ?-synuclein proteins can dramatically induce the
    formation of fibrous clumps of both proteins.

    “This newly uncovered interaction between these two proteins suggests
    that therapeutic agents created to directly or indirectly inhibit the
    formation of one form of amyloid lesion might be effective for treating
    other forms of amyloid lesions,” said Benoit Gaisson, PhD, lead author
    of the paper and researcher at the CNDR. “That is, a drug meant to keep
    Lewy bodies from forming to prevent Parkinson’s disease might also help
    prevent tau tangles from forming in Alzheimer’s disease.”

    The two proteins, tau and ?-synuclein are naturally abundant in the
    brain, but have distinct functions. Tau has a binding role in the
    structures of neurons, while ?-synuclein is thought to be involved in
    regulating communications in the synapses between neurons.

    The researchers knew that the smaller of the two proteins, ?-synuclein,
    could bind to itself in homogenous clumps. The tau protein, meanwhile,
    is larger and it requires co-factors to aid overcoming a folding
    threshold. While the Penn researchers initially demonstrated that
    ?-synuclein could aid tau into forming fibers in a test tube, the
    researchers also wanted to know if this also occurred in vivo. Using
    mouse models, they were able to demonstrate that ?-synuclein
    polymerization alone is sufficient to induce the assembly of tau clumps
    in cells of the brain. Moreover, they were able to demonstrate that the
    same phenomenon occurs in a similar group of individuals with a known
    genetic abnormality in the ?-synuclein gene.

    “After this initial step, we see a cycle begin to emerge,” said Gaisson.
    “Tau and ?-synuclein work together to promote and propagate each other’s
    formation of fibrous clumps and, hence, the amyloid lesions that cause
    disease.”
    ###
    Other scientists involved in the research paper described here include
    Mark S. Forman, Makoto Huguchi, Charles L. Graves, Paul T. Kotzbauer,
    and John Q. Trojanowski from Penn; and Lawrence I. Golbe from the
    University of Medicine and Dentistry of New Jersey-Robert Wood Johnson
    Medical School.

    Funding for this research was supported by the National Institutes on
    Aging and by a Pioneer Award from the Alzheimer’s Association.

    -- 
    Kathrynne Holden, MS, RD < fivestar@nutritionucanlivewith.com >
    "Ask the Parkinson Dietitian"  http://www.parkinson.org/
    "Eat well, stay well with Parkinson's disease"
    "Parkinson's disease: Guidelines for Medical Nutrition Therapy"
    http://www.nutritionucanlivewith.com/
    



    This archive was generated by hypermail 2b29 : Fri Apr 25 2003 - 04:16:48 PDT